Physician profile
Mike Cusnir
NPI 1962490631
$181,355.46
in general payments reported to CMS, 2019-2025
100 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $14K · 2021: $29K · 2022: $35K · 2023: $31K · 2024: $20K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Food and Beverage: $23K · Consulting Fee: $13K · Travel and Lodging: $1,453 · Education: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,785.00 |
| Food and Beverage | $22,728.12 |
| Consulting Fee | $13,373.00 |
| Travel and Lodging | $1,452.59 |
| Education | $633.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $83,178.87 | 2019-2024 | Sir-Spheres Microspheres |
| Ipsen Biopharmaceuticals, INC | $12,103.76 | 2019-2025 | Onivyde, Somatuline Depot, Tazverik |
| Eisai INC. | $7,925.97 | 2019-2025 | |
| Seagen INC. | $7,910.35 | 2019-2025 | Padcev, Tukysa, Adcetris |
| Astrazeneca Pharmaceuticals Lp | $7,519.80 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Jazz Pharmaceuticals INC. | $5,768.47 | 2022-2025 | Zepzelca |
| Celgene Corporation | $4,699.27 | 2019-2025 | Reblozyl, Pomalyst, Breyanzi |
| Novartis Pharmaceuticals Corporation | $4,596.52 | 2019-2025 | |
| Pfizer Chile S.A. | $4,310.96 | 2023 | |
| Lilly USA, LLC | $3,972.37 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Janssen Biotech, INC. | $2,956.27 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Pfizer INC. | $2,528.64 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $2,074.53 | 2019-2021 | |
| Beigene USA, INC. | $2,046.38 | 2021-2025 | Tevimbra, Brukinsa |
| Merck Sharp & Dohme LLC | $1,875.83 | 2019-2025 | Keytruda, Lynparza, Welireg |
Show all 99 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $1,800.59 | 2019-2025 | |
| Astellas Pharma US INC | $1,774.36 | 2019-2025 | Xospata, Xtandi, Padcev |
| Genentech USA, INC. | $1,622.73 | 2019-2025 | Polivy, Tecentriq, Venclexta |
| Incyte Corporation | $1,589.90 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Bayer Healthcare Pharmaceuticals INC. | $1,500.66 | 2019-2025 | |
| Array Biopharma INC | $1,338.38 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Genzyme Corporation | $1,310.13 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,114.78 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Daiichi Sankyo INC. | $1,031.96 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Emd Serono, INC. | $795.24 | 2019-2025 | Bavencio |
| Abbvie INC. | $746.85 | 2019-2025 | Venclexta |
| Amgen INC. | $722.69 | 2019-2023 | Kyprolis, Blincyto, Lumakras |
| Pharmacyclics LLC, An Abbvie Company | $697.69 | 2019-2023 | Epkinly, Imbruvica |
| Exelixis INC. | $646.27 | 2019-2025 | Cabometyx |
| Epizyme, INC. | $618.95 | 2020-2023 | Tazverik |
| Glaxosmithkline, LLC. | $592.51 | 2020-2025 | Ojjaara, Trelegy Ellipta, Jemperli |
| Gilead Sciences, INC. | $521.54 | 2019-2025 | Trodelvy |
| Sumitomo Pharma America, INC. | $459.33 | 2023-2025 | Orgovyx |
| Beigene, Ltd. | $450.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $436.25 | 2021-2025 | Ninlaro, Fruzaqla, Iclusig |
| Regeneron Healthcare Solutions, INC. | $435.15 | 2019-2025 | Libtayo |
| Tempus Ai, INC | $389.44 | 2024-2025 | Xt Cdx |
| Mirati Therapeutics, INC. | $384.77 | 2023-2024 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.23 | 2019-2025 | Gilotrif |
| Springworks Therapeutics, INC. | $333.00 | 2024-2025 | Ogsiveo, Gomekli |
| Deciphera Pharmaceuticals INC. | $316.74 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Dendreon Pharmaceuticals LLC | $313.79 | 2021-2025 | Provenge |
| Adaptive Biotechnologies Corporation | $305.45 | 2022-2025 | Clonoseq |
| Janssen Pharmaceuticals, INC | $299.10 | 2019-2025 | Xarelto |
| Clovis Oncology, INC. | $264.30 | 2019-2022 | |
| Beone Medicines USA, INC. | $262.37 | 2025 | Tevimbra, Brukinsa |
| Foundation Medicine, INC. | $237.69 | 2019-2023 | Foundationone Liquid Cdx |
| Karyopharm Therapeutics INC. | $233.91 | 2020-2025 | Xpovio |
| Myriad Genetic Laboratories, INC. | $219.93 | 2021-2025 | Myrisk |
| Sobi, INC | $193.12 | 2023-2025 | |
| Adc Therapeutics America, INC. | $189.77 | 2022-2023 | |
| Kite Pharma, INC. | $184.01 | 2020-2023 | Yescarta |
| Morphosys, US INC. | $181.75 | 2021-2023 | Monjuvi |
| G1 Therapeutics, INC. | $165.61 | 2021-2023 | Cosela |
| Eusa Pharma (US) LLC | $157.92 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $154.74 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Kyowa Kirin, INC. | $152.80 | 2019-2022 | |
| Tersera Therapeutics LLC | $146.15 | 2024-2025 | Zoladex |
| Servier Pharmaceuticals LLC | $140.84 | 2022-2025 | |
| Myovant Sciences INC. | $127.08 | 2021-2022 | |
| Genmab U.S., INC. | $111.53 | 2023 | Epkinly |
| Stemline Therapeutics INC. | $109.92 | 2023-2025 | Orserdu, Elzonris |
| Dova Pharmaceuticals | $106.41 | 2019-2021 | |
| Blueprint Medicines Corporation | $104.80 | 2024-2025 | Ayvakit |
| Aveo Pharmaceuticals, INC. | $104.22 | 2022-2025 | Fotivda |
| Intuitive Surgical, INC. | $93.69 | 2025 | |
| Caris Mpi, INC. | $88.63 | 2025 | Mi Cancer Seek |
| Geron Corporation | $84.69 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $84.44 | 2021-2024 | Ultomiris |
| Aurobindo Pharma USA, INC. | $81.74 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $81.29 | 2019-2025 | |
| Acceleron Pharma, INC. | $71.77 | 2021 | |
| Pharmacosmos Therapeutics INC. | $70.39 | 2024-2025 | Cosela, Monoferric |
| Tolmar, INC. | $68.64 | 2023-2025 | Rubraca, Eligard |
| Puma Biotechnology, INC. | $59.28 | 2022-2025 | |
| Agios Pharmaceuticals, INC. | $58.16 | 2024 | Pyrukynd |
| Pharmaand Gmbh | $54.13 | 2025 | Rubraca |
| Apellis Pharmaceuticals, INC. | $49.32 | 2023 | Empaveli |
| Syndax Pharmaceuticals, INC. | $47.13 | 2025 | |
| Alnylam Pharmaceuticals INC. | $41.17 | 2019 | |
| Recordati_rare_diseases_inc. | $40.87 | 2024 | Sylvant |
| Verastem, INC. | $34.63 | 2019 | |
| Cti Biopharma Corp. | $34.38 | 2023 | Vonjo |
| Janssen Scientific Affairs, LLC | $33.41 | 2019 | |
| Boston Scientific Corporation | $30.18 | 2022 | |
| Genentech, INC. | $25.54 | 2025 | Tecentriq |
| Immunogen, INC. | $24.78 | 2023 | Elahere |
| Helsinn Therapeutics (U.S.), INC. | $21.17 | 2019 | |
| Invivyd INC | $21.05 | 2025 | Pemgarda |
| Blue Earth Diagnostics | $19.50 | 2022 | |
| Nuvation Bio INC. | $19.04 | 2025 | Ibtrozi |
| Partner Therapeutics, INC. | $18.39 | 2020 | |
| Tesaro, INC. | $17.04 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $16.66 | 2022 | |
| Menarini Silicon Biosystems, INC. | $16.09 | 2025 | |
| Spectrum Pharmaceuticals INC. | $15.25 | 2019 | |
| Advanced Accelerator Applications | $13.41 | 2020 | |
| Shire North American Group INC | $10.87 | 2019 | |
| Veracyte, INC. | $0.39 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Sir-Spheres Microspheres $16KOnivyde $11KZiihera $5,471Braftovi $5,401Imfinzi $2,211Lonsurf $1,675Tevimbra $1,542Reblozyl $1,214Keytruda $849Orgovyx $816Erleada $765Sarclisa $728Enhertu $670Brukinsa $605Xtandi $575Lenvima $551Lynparza $509Kisqali $493Rybrevant $490Stivarga $437Krazati $423Carvykti $406Xt Cdx $389Libtayo $371Darzalex $365Nubeqa $352Mektovi $349Xofigo $340Talzenna $334Jakafi $332Elrexfio $322Pomalyst $319Pluvicto $310Inqovi $300Adcetris $297Monjuvi $284Provenge $283Venclexta $280Bosulif $269Tukysa $263Elahere $259Padcev $254Opdivo $252Tecvayli $252Vitrakvi $235Gilotrif $233Zepzelca $221Clonoseq $208Cabometyx $203Lorbrena $201Tivdak $193Ogsiveo $192Scemblix $180Xospata $179Ojjaara $179Qinlock $175Trodelvy $173Talvey $166Ayvakit $158Epkinly $157Zoladex $146Doptelet $140Pemazyre $138Myrisk $133Calquence $133Ninlaro $130Datroway $127Nexavar $120Lutathera $119Imbruvica $119Welireg $117Fabhalta $112Injectafer $111Rubraca $106Piqray $105Breyanzi $105Trelegy Ellipta $104Ibrance $101Bavencio $98.53Vyndaqel $95.00Da Vinci Surgical System $93.69Kyprolis $91.54Mi Cancer Seek $88.63Vonjo $87.73Verzenio $87.21Fotivda $85.41Polivy $85.05Rytelo $84.69Orserdu $83.33Xalkori $83.08Inlyta $82.73Zynyz $82.59Tecentriq $82.24Tibsovo $73.48Fruzaqla $72.97Akeega $72.87Iclusig $72.18Jaypirca $69.33Retevmo $67.14Blincyto $66.15
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mike Cusnir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.